Chronic Myeloid Leukemia (CML) Interactive Cases: An Immersive Simulated Learning Experience - Case 2: Navigating Loss of Response to First-Line Treatment for CML is organized by American Society of Hematology (ASH) and will be held from May 21, 2018 - May 21, 2019.
The target audience for this medical event is Hematologists, oncologists, and other healthcare professionals involved in the care and treatment of patients with CML. This CME Conference has been approved for a maximum of 2.5 Credit Hours.
CML Interactive Cases: An Immersive Simulated Learning Experience :
According to the American Cancer Society, chronic myeloid leukemia (CML) accounts for 15 to 20 percent of leukemias in adults. Management options for patients with CML include disease control using tyrosine kinase inhibitors, potential cure with allogeneic hematopoietic cell transplantation (HCT), and palliative therapy with cytotoxic agents. Among the factors that may inform treatment, a choice is a phase of CML, patient age, the presence of comorbidities, donor availability for HCT, and response to treatment with tyrosine kinase inhibitors.
This educational activity provides an opportunity to explore two different CML cases. Learners will navigate treatment decisions based on patient presentation, history, and other findings that may impact the therapeutic approach.
Case 2: Navigating Loss of Response to First-Line Treatment for CML :
A 65-year-old man with coronary artery disease and type 2 diabetes was diagnosed with CML three years ago and started treatment with first-line therapy following his CML diagnosis. The patient now experiences loss of response. This case explores possible reasons for treatment failure, monitoring and optimizing treatment adherence, monitoring treatment response and side effects, and multiple lines of therapy based on treatment history and risk.
Learning Objectives :
• Apply relevant information on new treatment developments appropriately to regimen/clinical trial selection
• Use timely and complete risk stratification and safety/tolerability risk assessment findings to inform treatment selection
• Explain defined milestones and related monitoring parameters that can inform optimal treatment choice
• Identify strategies for mitigating BCR-ABL TKI treatment nonadherence
Additional details will be posted as soon as they are available.